ASX listed PharmAust has revealed a timetable for the development of its promising anti-cancer drug as the Perth-based company moves ahead with human and canine trials. After pleasing results in Phase I human tests of its “Monepantel” drug, the company is pushing ahead with Phase II canine trials.
21/11/2016 - 15:35
PharmAust progresses anti-cancer drug clinical strategy
By Matt Birney
21/11/2016 - 15:35
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX